Part 2: Best Practices for Prescribing Opioids in Primary Care
Released On
December 15, 2023
Expires On
December 15, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Acute Care, Anesthesiology, Critical Care, Emergency Medicine, Geriatric Medicine, Hospice, Hospitalist, Neurology, Obstetrics & Gynecology, Pain Management, Pharmacy, Physiatry, Primary Care, Psychiatry, Rheumatology, Surgery
Topic(s)
Arthritis, CDC, Geriatric Medicine, Pain, Pharmacology, Rehabilitation, Rheumatoid Arthritis, Surgery
Acknowledgement
This activity is provided by Talem Health and RME Collaborative.
Supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS educational requirements issued by the US Food and Drug Administration.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 Nursing Contact Hour (0.5 contact hour of pharmacotherapy credit)
- Pharmacists — 1.0 Contact Hour (0.1 CEUs)
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed specifically for primary care clinicians, registered nurses, advanced practice registered nurses, pharmacists, and other members of the healthcare team.
Program Overview
Pain continues to be a major public health problem in the United States, causing reductions in patients’ daily function and quality of life. Despite the benefits of opioid analgesics, untreated and undertreated acute and chronic pain persists. Thus, education on safe opioid prescribing and comprehensive pain management remains essential to ensuring patients with pain are treated appropriately while mitigating potential risks. This CME/CE activity, which is Part 2 of a three-part series titled Tackling the Opioid Crisis: Strategies to Improve Best Practices and Patient Outcomes, will review components of an effective treatment plan including the establishment of treatment goals and multimodal management approaches with pharmacologic and nonpharmacologic interventions. Best practices for initiating treatment for acute and chronic pain, when to refer, and how to taper opioid therapy will also be discussed.
This activity meets most states’ requirements for opioid education and is fully compliant with the Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) education requirement issued by the FDA in September 2018.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Appropriately assess patients with pain and identify potential risk factors for abuse or addiction
- Develop an individualized plan of care to safely initiate opioid treatment, while maximizing efficacy and minimizing risks
- Describe the different therapeutic options for pain, including nonpharmacologic approaches and pharmacologic (nonopioid and opioid analgesics) therapies
- Review general and product-specific information about immediate-release (IR) and extended-release/long-acting (ER/LA) opioid analgesics
Faculty
Michael J. Brennan, MD
Medical Director, Pain Center of Fairfield
Fairfield, CT
Senior Attending Physician, Department of Medicine, Physical Medicine, and Rehabilitation
Bridgeport Hospital
Bridgeport, CT
Jeffrey A. Gudin, MD
Professor of Anesthesiology, Perioperative Medicine, and Pain Management
University of Miami, Miller School of Medicine
Miami, FL
Joint Accreditation Statement
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Continuing Pharmacy Education
Talem Health designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008332-0000-23-018-H08-P)
Type of Activity: Application
For Pharmacists: Upon successfully completing the post-test with a score of 67% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.
Disclosure of Conflicts of Interest
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Michael J. Brennan, MD, has disclosed the following relevant financial relationships: speakers’ bureau for SCILEX Pharmaceuticals, Inc.
Jeffrey A. Gudin, MD, has disclosed the following relevant financial relationships: consultant for Collegium Pharmaceutical, Inc., Hisamitsu Pharmaceutical Co., Inc., Quest Diagnostics, and Sanofi; and grant/research support and stock ownership interest in Virpax Pharmaceuticals.
Planners, Managers, and Reviewer
Barbara P. Yawn, MD, MSc, FAAFP, has disclosed the following relevant financial relationships: consultant for Teva Pharmaceuticals.
Gabriela Pankow, RN, has no relevant financial relationships to disclose.
Instructions for Participation and Credit
This activity is offered at no cost to participants. To receive CME credit, participants must:
- Read the CME/CE information, including learning objectives and disclosure statements.
- Complete the pre-test.
- View the online activity.
- Complete the post-test and evaluation form.
A post-test score of 67% or higher is required to obtain credit. Your certificate will be made available for immediate download.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.
Media
Internet activity
Fee Information
There is no fee for this educational activity.
Contact Information
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or [email protected].